Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD)
E. White (Ann Arbor, Michigan, United States of America), J. Behr (Munich, Germany), M. Kolb (Hamilton, Ontario, Canada), T. Maher (London, United Kingdom), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), B. Crestani (Paris, France)
Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. White (Ann Arbor, Michigan, United States of America), J. Behr (Munich, Germany), M. Kolb (Hamilton, Ontario, Canada), T. Maher (London, United Kingdom), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), B. Crestani (Paris, France). Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD). 731
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: